伴PLZF/RARα阳性急性早幼粒细胞白血病的治疗:附1例报告并文献复习

详细信息

收稿日期: 2012-02-15

Combination of arsenic trioxide and chemotherapy in the treatment of PLZF/RARα positive acute promyelocytic leukemia patient: a case report and literature review

- Institute of Hematology&Blood Disease Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, 300020, China

More Information

Received Date: 15 February 2012

摘要: 目的:提高对伴PLZF/RARα融合基因阳性的急性早幼粒细胞白血病(APL)诊断和治疗的认识。方法:报道1例伴PLZF/RARα融合基因阳性APL的诊断、治疗经过及随访情况。结果:患者经骨髓形态学、组织化学、免疫分型、染色体、融合基因等检查确诊为APL伴PLZF/RARα融合基因阳性,予以三氧化二砷(ATO)联合化疗达到完全缓解(CR)后,继续予以ATO联合化疗强化巩固治疗。随访11个月,患者仍处于CR1期。结论:伴PLZF/RARα融合基因阳性APL可采用ATO联合化疗诱导、巩固治疗,延长患者生存时间。
- 白血病,早幼粒细胞性,急性 /
- 三氧化二砷 /
- 化疗 /
- PLZF/RARα
Abstract: Objective:To improve the diagnosis and therapy of acute promyelocytic leukemia(APL)with positive PLZF/RARα fusion gene.Method:We reviewed the patient's clinical features,laboratory results,treatment and following up.Result:This patient was diagnosed APL with PLZF/RARαa(+)by morphologic,immunophenotypic,histochemistry,genetic and molecular studies.Complete hematologic remission was obtained after induction chemotherapy which used arsenic trioxide(ATO)with combined chemotherapy.Until now,the patient was still in CR1.Conclusion:The patient with PLZF/RARαa(+)can achieve CR and prolong the survival time through ATO with combined chemotherapy.
- acute promyelocytic leukemia /
- arsenic trioxide /
- chemotherapy /
- PLZF/RARα

[1]	STIREWALT D L,RADICH J P.The role of FLT3 in haematopoietic malignancies[J].Nat Rev Cancer,2003,3:650-665.
[2]	MORI S,CORTES J,KANTARJIAN H,et al.Potential role of sorafenib in the treatment of acute myeloid leukemia[J].Leuk Lymphoma,2008,49:2246-2255.
[3]	AUCLAIR D,MILLER D,YATSULA V,et al.Antitumor activity of sorafenib in FLT3-driven leukemic cells[J].Leukemia,2007,21:439-445.
[4]	ZHANG W,KONOPLEVA M,SHI Y X,et al.Mutant FLT3:a direct target of sorafenib in acute myelogenous leukemia[J].J Natl Cancer Inst,2008,100:184-198.
[5]	BORTHAKUR G,KANTARJIAN H,RAVANDI F,et al.Phase I study of sorafenib in patients with refractory or relapsed acute leukemias[J].Haematologica,2011,96:62-68.
[6]	RAVANDI F,CORTES J E,JONES D,et al.Phase I/II study of combination therapy with sorafenib,idarubicin,and cytarabine in younger patients with acute myeloid leukemia[J].J Clin Oncol,2010,28:1856-1862.
[7]	METZELDER S,WANG Y,WOLLMER E,et al.Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia:sustained regression before and after allogeneic stem cell transplantation[J].Blood,2009,113:6567-6571.